All In Biotech

Drug Trial Radar · NCT07550231

Determining the Optimal Dose of AD-211 in Patients With Osteoarthritis of the Knee

A Randomized, Double-Blind, Parallel, Multi-Center, Phase 2 Clinical Trial to Determine the Optimal Dose of AD-211 in Patients With Osteoarthritis of the Knee

Last checked: Nov 19, 2026Latest source record: Apr 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Jun 2026

Primary completion

Mar 2027

Study completion Mar 2027

Sponsor

Lead sponsor
Addpharma Inc.Industry
Sponsor type
Industry
First posted
Apr 24, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the optimal dose of AD-211 in patients with osteoarthritis of the knee.

Conditions

  • Osteoarthritis of the Knees

Interventions

  • AD-211-LDrug

    Per oral, 1 tablet twice daily during the treatment period.

  • AD-211-MDrug

    Per oral, 1 tablet twice daily during the treatment period.

  • AD-211-HDrug

    Per oral, 1 tablet twice daily during the treatment period.

  • AD-2113Drug

    Per oral, 1 tablet twice daily during the treatment period.

  • Placebo to AD-211-L/MDrug

    Per oral, 1 tablet twice daily during the treatment period.

  • Placebo to AD-211-HDrug

    Per oral, 1 tablet twice daily during the treatment period.

  • Placebo to AD-2113Drug

    Per oral, 1 tablet twice daily during the treatment period.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in 100 mm Pain VAS score during activity over the past 24 hours in the target kneeTime frame: Baseline to Week13

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.